Gene
CDK6
CDK6 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (1), Actionable biomarkers (7), Trial mentions (36), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CDK6. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 10 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 2 of 8,597 | 0.02% | not measured | |
| 2023 | 3 of 8,275 | 0.04% | 27 of 11,460 | 0.24% |
| 2022 | 0 of 8,285 | 0.00% | 37 of 13,598 | 0.27% |
| 2021 | 4 of 8,692 | 0.05% | 38 of 15,045 | 0.25% |
| 2020 | 2 of 7,640 | 0.03% | 36 of 14,459 | 0.25% |
| 2019 | 4 of 7,300 | 0.05% | 43 of 12,159 | 0.35% |
| 2018 | 3 of 6,927 | 0.04% | 27 of 11,854 | 0.23% |
| 2017 | 8 of 6,558 | 0.12% | 29 of 11,595 | 0.25% |
Showing 10 of 37 years.
Assay-provider ledger (1)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Illumina | Unclassified | Clinical validationAnalytical validation | 1 | May 10, 2015 |
Actionable biomarkers (7)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CDK6 amplification | Lee011 | response-associated | liposarcoma | Cancer Genome Interpreter |
| CDK6 oncogenic mutation | Lee011 | response-associated | liposarcoma | Cancer Genome Interpreter |
| CDK6 amplification | Lee011 | response-associated | lymphoma | Cancer Genome Interpreter |
| CDK6 oncogenic mutation | Lee011 | response-associated | lymphoma | Cancer Genome Interpreter |
| CDK6 amplification | Lee011 | response-associated | No disease recorded | Cancer Genome Interpreter |
Showing 5 of 7 actionable-biomarker assertions.
Trial mentions (36)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT03310879 | Trial eligibility (AACT) |
| NCT05999968 | Trial eligibility (AACT) |
| NCT05866692 | Trial eligibility (AACT) |
| NCT04040205 | Trial eligibility (AACT) |
| NCT05563220 | Trial eligibility (AACT) |
Showing 5 of 36 trial mentions.
Target-disease associations (591)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| AMED syndrome, digenic | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Abdominal Aortic Aneurysm | cardiovascular disease | GWAS credible sets |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
Showing 5 of 591 associations.
Vendor sourcing (102)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Academic and Community Cancer Research United | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | * Any of the following prior therapies: * Surgery =\< 21 days prior to pre-registration * Chemotherapy =\< 21 days prior to pre-registration * Radiat... | View trial NCT04351230 |
| Academic and Community Cancer Research United | Trial sponsor | Mentioned in trial textTrial free-text mention | CDK6 | View trial NCT04351230 |
| Alliance for Clinical Trials in Oncology | Trial sponsor | Mentioned in trial textTrial free-text mention | CDK6 | View trial NCT02523014 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.700G>A (p.V234M) alteration is located in exon 7 (coding exon 6) of the CDK6 gene. This alteration results from a G to A substitution at nucleotide pos... | View ClinVar record SCV003760181.2 |
| Bayer (Germany) | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | : * Prior treatment with cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) inhibitors or darolutamide. * Prior systemic therapy for metastatic castration-resi... | View trial NCT05999968 |
Showing 5 of 102 sourcing records.
Trial-cited literature (380)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. | The Lancet. Oncology | 2025 | 3 |
| The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia. | Blood neoplasia | 2025 | 3 |
| A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer. | Cancer research communications | 2025 | 1 |
| Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing. | International journal of molecular sciences | 2025 | 1 |
| Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. | Cancer discovery | 2024 | 228 |
Showing 5 of 380 papers.
Protein variant mentions (4)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A259T | 1 | 2015 | PMID 25741868 |
| p.D110N | 1 | 2015 | PMID 25741868 |
| p.Q12H | 1 | 2017 | PMID 28533223 |
| p.S317C | 1 | 2015 | PMID 25741868 |
Literature-extracted relations (141)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| FULVESTRANT | Chemical | negative_correlate |
Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. | 2023 |
| TRASTUZUMAB | Chemical | negative_correlate |
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN). | 2023 |
| Letrozole | Chemical | negative_correlate |
A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer. | 2022 |
| Letrozole | Chemical | negative_correlate |
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. | 2021 |
| EVEROLIMUS | Chemical | associate |
Ribociclib and everolimus in well-differentiated foregut neuroendocrine tumors. | 2021 |
Showing 5 of 141 relation assertions.
Organizations publishing (486)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Dana-Farber Cancer Institute | Other | 28 | 2011 to 2025 |
| Memorial Sloan Kettering Cancer Center | Hospital | 27 | 2012 to 2024 |
| Harvard Medical School | Academic | 21 | 2009 to 2024 |
| The University of Texas System | Academic | 16 | 2009 to 2024 |
| Mayo Clinic | Hospital | 11 | 2013 to 2025 |
Showing 5 of 486 organizations.
Where CDK6 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
519 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.